Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Tevogen Bio CEO Dr. Ryan Saadi will join a key panel discussion at BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025. The panel, "Paths to Liquidity: Strategies for Adapting to a Volatile Market," will feature experts from J.P. Morgan, RSM, and Cantor Fitzgerald.
The conference, hosted at The Liberty Science Center in Jersey City, NJ, aims to connect investors, business development professionals, and industry executives to boost strategic partnerships and funding opportunities. The event includes:
- One-on-one partnering sessions
- Company pitch presentations
- Industry Connections Desk
- Exhibits and networking opportunities
- Plenary discussions
Dr. Saadi emphasized the critical timing of addressing market volatility and its impact on patient outcomes, aligning with Tevogen's mission to improve access to affordable lifesaving treatments.
Il CEO di Tevogen Bio, il dottor Ryan Saadi, parteciperà a una discussione chiave durante il Quindicesimo Annuale Bio Partnering Conference di BioNJ il 13 maggio 2025. Il panel, intitolato "Percorsi verso la Liquidità: Strategie per Adattarsi a un Mercato Volatile," vedrà la partecipazione di esperti di J.P. Morgan, RSM e Cantor Fitzgerald.
La conferenza, che si terrà presso il Liberty Science Center di Jersey City, NJ, ha l'obiettivo di mettere in contatto investitori, professionisti dello sviluppo commerciale e dirigenti del settore per favorire partnership strategiche e opportunità di finanziamento. L'evento comprende:
- Sessioni di incontro one-to-one
- Presentazioni aziendali
- Desk per connessioni industriali
- Esposizioni e opportunità di networking
- Discussioni plenarie
Il dottor Saadi ha sottolineato l'importanza del momento per affrontare la volatilità del mercato e il suo impatto sui risultati per i pazienti, in linea con la missione di Tevogen di migliorare l'accesso a trattamenti salvavita a prezzi accessibili.
El CEO de Tevogen Bio, el Dr. Ryan Saadi, participará en un panel clave durante la Decimoquinta Conferencia Anual de Bio Partnering de BioNJ el 13 de mayo de 2025. El panel, titulado "Caminos hacia la Liquidez: Estrategias para Adaptarse a un Mercado Volátil," contará con expertos de J.P. Morgan, RSM y Cantor Fitzgerald.
La conferencia, que se llevará a cabo en el Liberty Science Center en Jersey City, NJ, tiene como objetivo conectar inversores, profesionales de desarrollo comercial y ejecutivos de la industria para impulsar asociaciones estratégicas y oportunidades de financiamiento. El evento incluye:
- Sesiones de asociación uno a uno
- Presentaciones de empresas
- Mostrador de conexiones industriales
- Exposiciones y oportunidades de networking
- Discursos plenarios
El Dr. Saadi enfatizó la importancia de abordar la volatilidad del mercado y su impacto en los resultados para los pacientes, alineándose con la misión de Tevogen de mejorar el acceso a tratamientos salvavidas asequibles.
Tevogen Bio의 CEO인 Dr. Ryan Saadi가 2025년 5월 13일 BioNJ 제15회 연례 바이오 파트너링 컨퍼런스의 주요 패널 토론에 참여합니다. '유동성으로 가는 길: 변동성이 큰 시장에 적응하기 위한 전략'이라는 패널에는 J.P. Morgan, RSM, Cantor Fitzgerald의 전문가들이 참여합니다.
뉴저지주 저지시티에 위치한 리버티 사이언스 센터에서 개최되는 이 컨퍼런스는 투자자, 사업 개발 전문가 및 업계 임원들을 연결하여 전략적 파트너십과 자금 조달 기회를 증진하는 것을 목표로 합니다. 행사에는 다음이 포함됩니다:
- 1대1 파트너링 세션
- 기업 피치 발표
- 산업 연결 데스크
- 전시 및 네트워킹 기회
- 전체 토론
Saadi 박사는 시장 변동성과 그것이 환자 결과에 미치는 영향에 대한 시기적절한 대응의 중요성을 강조하며, 이는 Tevogen의 저렴한 생명 구호 치료 접근성 향상이라는 사명과 일치한다고 밝혔습니다.
Le PDG de Tevogen Bio, le Dr Ryan Saadi, participera à une table ronde clé lors de la quinzième conférence annuelle de Bio Partnering de BioNJ le 13 mai 2025. Le panel intitulé « Voies vers la liquidité : stratégies pour s'adapter à un marché volatile » réunira des experts de J.P. Morgan, RSM et Cantor Fitzgerald.
La conférence, organisée au Liberty Science Center à Jersey City, NJ, vise à connecter investisseurs, professionnels du développement commercial et cadres de l'industrie afin de favoriser des partenariats stratégiques et des opportunités de financement. L'événement comprend :
- Sessions de partenariat en tête-à-tête
- Présentations d'entreprises
- Guichet des connexions industrielles
- Expositions et opportunités de réseautage
- Discussions plénières
Le Dr Saadi a souligné l'importance cruciale d'aborder la volatilité du marché et son impact sur les résultats pour les patients, en accord avec la mission de Tevogen d'améliorer l'accès à des traitements vitaux abordables.
Dr. Ryan Saadi, CEO von Tevogen Bio, wird am 13. Mai 2025 an einer wichtigen Podiumsdiskussion auf der 15. jährlichen Bio Partnering Conference von BioNJ teilnehmen. Das Panel mit dem Titel „Wege zur Liquidität: Strategien zur Anpassung an einen volatilen Markt“ wird Experten von J.P. Morgan, RSM und Cantor Fitzgerald umfassen.
Die Konferenz, die im Liberty Science Center in Jersey City, NJ, stattfindet, hat zum Ziel, Investoren, Geschäftsentwicklungsexperten und Branchenführer zu vernetzen, um strategische Partnerschaften und Finanzierungsmöglichkeiten zu fördern. Die Veranstaltung beinhaltet:
- Einzelgespräche
- Unternehmenspräsentationen
- Industry Connections Desk
- Ausstellungen und Networking-Möglichkeiten
- Plenardiskussionen
Dr. Saadi betonte die entscheidende Bedeutung, die Marktvolatilität und deren Auswirkungen auf Patientenergebnisse zum richtigen Zeitpunkt anzugehen, was mit Tevogens Mission übereinstimmt, den Zugang zu erschwinglichen lebensrettenden Behandlungen zu verbessern.
- CEO participation in high-profile panel with experts from major financial institutions (J.P. Morgan, RSM, Cantor Fitzgerald) increases company visibility
- Strategic networking opportunity with investors and BD professionals could lead to potential partnerships
- None.
WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.
The conference, held on May 13, 2025, at The Liberty Science Center in Jersey City, NJ, historically brings together investors, BD professionals, academic collaborators, innovators and biopharmaceutical industry executives to foster strategic partnerships, drive funding, and accelerate collaboration, with the ultimate goal of advancing medical innovation and transforming the future of healthcare.
“I look forward to joining in the upcoming panel discussion hosted by BioNJ,” said Dr. Saadi. “This is a critical moment for the biotechnology industry to address market volatility and its potential impact on patient outcomes. The topic is closely aligned with Tevogen Bio’s mission to advance accessibility and affordability to lifesaving treatments.”
“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to welcome Dr. Saadi and his fellow panelists to share their invaluable insights during “Paths to Liquidity: Strategies for Adapting to a Volatile Market”. Attendees are certain to walk away with meaningful, actionable takeaways.”
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When and where is BioNJ's 15th Annual Bio Partnering Conference featuring Tevogen's CEO?
What is the focus of Tevogen (TVGNW) panel discussion at BioNJ 2025 conference?
Who are the key speakers joining Tevogen CEO at BioNJ's 2025 biotech panel?
What networking opportunities does BioNJ 2025 conference offer biotech investors?
How does the BioNJ 2025 conference align with Tevogen's business goals?
